Lund Melanoma Study Group
81 – 90 of 258
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy : A Population-Based Cohort Study
- Contribution to journal › Article
-
Mark
Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence : A Nested Case-Control Study
- Contribution to journal › Article
-
Mark
Trend shifts in age-specific incidence for in situ and invasive cutaneous melanoma in sweden
- Contribution to journal › Article
-
Mark
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
- Contribution to journal › Article
-
Mark
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
- Contribution to journal › Article
-
Mark
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma
- Contribution to journal › Article
-
Mark
Mendelian randomisation study of smoking exposure in relation to breast cancer risk
- Contribution to journal › Article
-
Mark
Common Susceptibility Loci for Male Breast Cancer
- Contribution to journal › Article
-
Mark
Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer : A prospective cohort study
- Contribution to journal › Article
-
Mark
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
- Contribution to journal › Article
